LEXICON PHARMACEUTICALS, INC. reported quarter ended March 31, 2026 results: revenue $21.1 million.
“Total revenues were $21.1 million for the first quarter of 2026”
LEXICON PHARMACEUTICALS, INC. — fact timeline
Source-grounded facts extracted from LEXICON PHARMACEUTICALS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
LEXICON PHARMACEUTICALS, INC. issued 691,823 shares of warrant to Hercules Capital, Inc. and certain of its affiliates for $1.59 per share.
“shares of its common stock equal to 2% of the aggregate principal amount of the Hercules Term Loans made and funded under the loan and security agreement at an exercise price of $1.59 per share. Concurrent with the funding of the first tranche, Lexicon granted Hercules warrants to purchase 691,823 shares of its common stock. Upon funding of the second and third”
LEXICON PHARMACEUTICALS, INC. incurred credit facility of up to $100 million in borrowing capacity with Hercules Capital, Inc. and certain of its affiliates at prime rate plus 3.10%, but not less than 9.85% maturing May 2030.
“On May 4, 2026, Lexicon Pharmaceuticals, Inc. (" Lexicon ") and its subsidiaries entered into a loan and security agreement with Hercules Capital, Inc. and certain of its affiliates (" Hercules ") that provides up to $100 million in borrowing capacity (the " Hercules Term Loans ") available in three tranches, each maturing in May 2030.”
LEXICON PHARMACEUTICALS, INC. entered into Loan and Security Agreement with Hercules Capital, Inc. and certain of its affiliates valued at up to $100 million (effective 2026-05-04).
“On May 4, 2026, Lexicon Pharmaceuticals, Inc. (“ Lexicon ”) and its subsidiaries entered into a loan and security agreement with Hercules Capital, Inc. and certain of its affiliates (“ Hercules ”) that provides up to $100 million in borrowing capacity”
LEXICON PHARMACEUTICALS, INC.: Increased authorized common stock from 450,000,000 to 900,000,000 (effective 2026-04-30).
“The Seventh Amended and Restated Certificate of Incorporation increases the number of shares of our authorized Common Stock from 450,000,000 to 900,000,000.”
LEXICON PHARMACEUTICALS, INC. issued 184,365.8 shares of its Series B Convertible Preferred Stock of preferred stock to affiliate of Invus for $65 per share.
“on January 29, 2026, the Company entered into a Preferred Stock Purchase Agreement with an affiliate of Invus (the “ Preferred Private Placement Purchaser ” and, such agreement, the “ Preferred Purchase Agreement ”), pursuant to which the Company agreed to (i) sell 184,365.8 shares of its Series B Convertible Preferred Stock, par value $0.01 per share (the “ Preferred Stock ”), at a price of $65 per share in a private placement in partial satisfaction of the Invus Entities’ preemptive right under the Certificate of Incorporation”
LEXICON PHARMACEUTICALS, INC. issued 22,400,000 shares of Common Stock of common stock to Artal Participations S.à r.l., Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Invus US Partners LLC, Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus, L.P., Siren, LLC, Ulys, L.L.C. and Mr. Raymond Debbane for $29.12 million.
“and Restated Certificate of Incorporation (the “ Certificate of Incorporation ”). The total purchase price of the Common Stock purchased by the Private Placement Purchasers was $29.12 million. The Common Stock Purchase Agreement incorporates the representations and warranties and covenants made by the Company in the Underwriting Agreement for the benefit of the”
LEXICON PHARMACEUTICALS, INC.: Filing of Certificate of Designations for Series B Convertible Preferred Stock, including terms for automatic conversion conditioned on stockholder approval of a new charter increasing authorized common shares (effective 2026-02-02).
“On February 2, 2026, in connection with the Preferred Private Placement, the Company filed with the Secretary of State of the State of Delaware to be effective upon filing the Certificate of Designations of Series B Convertible Preferred Stock of the Company (the “ Certificate of Designations ”), in the form approved and adopted by the board of directors of the Company, which sets forth the terms of the Preferred Stock.”
LEXICON PHARMACEUTICALS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“January 3, 2025, we received a letter (the “Notice”) from the Listing Qualifications staff of The NASDAQ Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of our common stock for the last 31 c”
Kristen L. Alexander changed role as vice president, finance and accounting at LEXICON PHARMACEUTICALS, INC..
“Kristen L. Alexander, our vice president, finance and accounting, relinquished her function as our principal financial officer.”
Scott M. Coiante was appointed as senior vice president and chief financial officer at LEXICON PHARMACEUTICALS, INC..
“Effective as of January 2, 2025, Scott M. Coiante was appointed as our senior vice president and chief financial officer, in which capacity he will function as our principal financial officer.”
LEXICON PHARMACEUTICALS, INC. announced a restructuring with charges of $9.0 million to $10.5 million affecting commercial operations and across all functions (reduce our workforce by approximately sixty percent).
“On November 22, 2024 we determined to eliminate our commercial operations and rationalize resources across all functions in order to preserve cash and focus our resources on advancing our clinical development pipeline. In connection with such determination, we intend to implement a reduction in force which will reduce our workforce by approximately sixty percent. We estimate that we will incur an aggregate of approximately $9.0 million to $10.5 million in pre-tax charges in connection with severance and other employee costs associated with the reduction in force, most of which will be paid in the first quarter of 2025 and all of which are expected to be cash expenditures.”
Ivan H. Cheung was elected as director at LEXICON PHARMACEUTICALS, INC..
“On November 19 , 2024, our board of directors elected Ivan H. Cheung to serve as a member of our board of directors, effective as of December 2, 2024.”
Robert J. Lefkowitz, M.D. retired as director at LEXICON PHARMACEUTICALS, INC..
“On November 19, 2024, Robert J. Lefkowitz, M.D. notified us of his decision to retire from our board of directors, effective as of December 2, 2024.”
Kristen L. Alexander was appointed as Principal Financial Officer at LEXICON PHARMACEUTICALS, INC..
“Effective as of the date of termination of Mr. Wade’s employment, Kristen L. Alexander will assume the function of our principal financial officer.”
Jeffrey L. Wade was terminated as President and Chief Operating Officer at LEXICON PHARMACEUTICALS, INC..
“On September 13, 2024, we and Jeffrey L. Wade determined that his employment as our president and chief operating officer (in which capacity, Mr. Wade has functioned as our principal financial officer) would terminate as of September 30, 2024.”
Michael Exton was elected as Director at LEXICON PHARMACEUTICALS, INC..
“elected to serve as a member of our board of directors”
Michael Exton was appointed as Chief Executive Officer at LEXICON PHARMACEUTICALS, INC..
“Michael Exton, Ph.D. was appointed as our chief executive officer”
LEXICON PHARMACEUTICALS, INC.: Amended and restated certificate of incorporation to increase authorized common stock from 300,000,000 to 450,000,000 shares (effective 2024-05-10).
“On May 10, 2024, we filed a Sixth Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware, which became effective on the filing date. The Sixth Amended and Restated Certificate of Incorporation increases the number of shares of our authorized Common Stock from 300,000,000 to 450,000,000.”
LEXICON PHARMACEUTICALS, INC. shareholders approved Ratification and approval of the appointment of Ernst & Young LLP as Company's independent auditors for the fiscal year ending December 31, 2024 at the 2024-05-10 meeting.
“(4) Ratification and approval of the appointment of Ernst & Young LLP as Company's independent auditors for the fiscal year ending December 31, 2024 286,136,766 2,884,465 414,731”
LEXICON PHARMACEUTICALS, INC. shareholders approved Advisory vote to approve the compensation paid to the Company's named executive officers at the 2024-05-10 meeting.
“(3) Advisory vote to approve the compensation paid to the Company’s named executive officers 253,593,322 6,203,593 623,318”
LEXICON PHARMACEUTICALS, INC. shareholders approved Ratification and approval of the Company's Sixth Amended and Restated Certificate of Incorporation at the 2024-05-10 meeting.
“(2) Ratification and approval of the the Company’s Sixth Amended and Restated Certificate of Incorporation 160,676,391 1,433,806 211,035”
LEXICON PHARMACEUTICALS, INC. shareholders approved Election of Class III Directors at the 2024-05-10 meeting.
“(1) Election of Class III Directors Name of Director For Withheld Broker Non-Votes Philippe J. Amouyal 241,812,501 18,607,732 29,015,729”
LEXICON PHARMACEUTICALS, INC. reported three months ended March 31, 2024 results: revenue $1.1 million, net income $48.4 million, or $0.20 per share.
“continues to progress, with favorable feedback from healthcare providers and ongoing negotiations with payers regarding expanded market access. Net sales for the quarter were $1.1 million reflecting 63 percent growth from the previous quarter. Market access remains at approximately 40% overall and is expected to expand in the second half of 2024. ZYNQUISTA”
Lonnel Coats retired as Member of the Board of Directors at LEXICON PHARMACEUTICALS, INC..
“On April 24, 2024, Lonnel Coats notified us of his retirement as our chief executive officer (in which capacity, Mr. Coats functions as our principal executive officer) and as a member of our board of directors, in each case effective July 7, 2024.”
Lonnel Coats retired as Chief Executive Officer at LEXICON PHARMACEUTICALS, INC..
“On April 24, 2024, Lonnel Coats notified us of his retirement as our chief executive officer (in which capacity, Mr. Coats functions as our principal executive officer) and as a member of our board of directors, in each case effective July 7, 2024.”
LEXICON PHARMACEUTICALS, INC.: Filing of Certificate of Designations for Series A Convertible Preferred Stock and planned increase in authorized common shares from 300,000,000 to 450,000,000 upon stockholder approval and adoption of New Charter (effective 2024-03-12).
“On March 12, 2024, in connection with the previously announced private placement by Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), of preferred stock to be designated as Series A Convertible Preferred Stock, par value $0.01 per share (the “ Preferred Stock ”), the Company filed with the Secretary of State of the State of Delaware to be effective upon filing the Certificate of Designations of Series A Convertible Preferred Stock of the Company (the “ Certificate of Designations ”), in the form approved and adopted by the board of directors of the Company, which sets forth the terms of the Preferred Stock.”
LEXICON PHARMACEUTICALS, INC. reported the three months ended December 31, 2023 results: revenue $0.7 million, net income $48.2 million, EPS $0.20 per share.
“are for the fourth quarter and full year of 2023 compared to the fourth quarter and full year of 2022. Revenues: Revenues for the fourth quarter and full year of 2023 were $0.7 million and $1.2 million, respectively, primarily from the commercialization of INPEFA. Research and Development (R&D) Expenses: Research and development expenses for the fourth quarter”
LEXICON PHARMACEUTICALS, INC. amended Fifth Amendment with Oxford Finance LLC (effective 2024-03-06).
“On March 6, 2024, the Company and one of its subsidiaries entered into a fifth amendment to its loan and security agreement (the “ Fifth Amendment ”) with Oxford Finance LLC and the lenders listed therein modifying the existing financial covenant relating to net sales of INPEFA ® (sotagliflozin).”
LEXICON PHARMACEUTICALS, INC. entered into Preferred Stock Purchase Agreement with certain accredited investors valued at approximately $250 million (effective 2024-03-11).
“On March 11, 2024, Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), entered into a Preferred Stock Purchase Agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Purchasers ”).”
LEXICON PHARMACEUTICALS, INC. amended Fourth Amendment to Loan and Security Agreement with Oxford Finance LLC valued at Modified financial covenants relating to net sales of INPEFA and minimum cash balance; extended avai (effective 2023-12-29).
“On December 29, 2023, Lexicon and one of its subsidiaries entered into a fourth amendment (the “ Fourth Amendment ”) to its loan and security agreement (the “ Loan Agreement ”) with Oxford Finance LLC and the lenders listed therein. Under the terms of the Fourth Amendment, the existing financial covenants relating to net sales of INPEFA ® (sotagliflozin) and minimum cash balance requirements were each modified, with the financial covenant relating to minimum cash balance requirements becoming immediately effective rather than upon Lexicon’s exercise of its option to fund the fourth tranche and following its funding. Such fourth tranche, under which $25 million was previously available for draw at Lexicon’s option between December 1 and December 31, 2023, will now be available upon the achievement of specified INPEFA net sales and until April 15, 2025. Lexicon may not extend the initial 36-month interest-only period to 48 months at its option as previously contemplated. The foregoing su”
LEXICON PHARMACEUTICALS, INC. entered into Open Market Sale Agreement with Jefferies LLC valued at up to $75,000,000 (effective 2023-12-29).
“On December 29, 2023, Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”) entered into an Open Market Sale Agreement SM (the “ Agreement ”) with Jefferies LLC, as sales agent (“ Jefferies ”), pursuant to which the Company may offer and sell, from time to time, through Jefferies (the “public offerings”), shares of its common stock, par value $0.001, having an aggregate sales price of up to $75,000,000 (the “ Shares ”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.